Becketts advises Telix Pharmaceuticals on its acquisition of Lightpoint Medical Ltd (UK)

Telix is an ASX-listed (ASX: TLX) biopharmaceuticals company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe and Japan.

Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals. The acquisition of Lightpoint and its SENSEI® radio-guided surgery business is expected to strengthen Telix’s capabilities in deploying molecular imaging in the surgical setting.

The Becketts team which advised Telix on the transaction included Alex Bean and Nick Golding, Partners, supported by Rachel Morris, Senior Associate and Brad Papaluca, Lawyer.  Telix’s UK lawyers on the transaction were Bristows, LLP with the team led by David Horner, Partner and Jamie May, Associate.